-
-
-
-
A new study points out the risk of nonsteroidal anti-inflammatory drug (NSAID) use in patients who have had a myocardial infarction (MI) suggesting that even brief use increases the risk for death and recurrent MI.
-
The FDA has approved linagliptin for the treatment of type 2 diabetes in adults.
-
The FDA has approved two new drugs for the treatment of hepatitis C the first new drugs to be approved in years.
-
Niacin may not be effective in preventing cardiovascular disease.
-
With the advent of new vaccines, the incidence of bacterial meningitis has declined, particularly in children, but the mortality rate has remained the same.
-
Variant Creutzfeldt-Jakob disease usually presents with subtle psychiatric symptoms and there is usually a significant delay in diagnosis.
-
Patients originally on interferon beta-1a in the TRANSFORMS study were re-randomized to either 0.5 or 1.25 mg of fingolimod. There was a reduction in relapse rate and MRI activity in patients that switched to fingolimod without an increase in severe adverse events.
